IMVT Stock Analysis: Immunovant | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 8.799m USD | 12M Return: 163.2% | US45258J1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 38.3M
Qual. Beats: -1
Qual. Beats: 1
Warnings
Tailwinds
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Immunovant, Inc. is a clinical-stage immunology company developing monoclonal antibody therapies for autoimmune diseases. Its lead candidate, IMVT-1402, inhibits the neonatal Fc receptor and is being studied for conditions including Graves disease, rheumatoid arthritis, Sjögrens disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy.
Founded in 2018 and based in Durham, North Carolina, Immunovant operates as a subsidiary of Roivant Sciences Ltd., which uses a hub-and-spoke model in which dedicated biotech entities are formed around individual therapeutic programs. As a clinical-stage company with no approved products, Immunovants value is tied to pipeline and clinical-trial outcomes rather than commercial revenue.
- IMVT-1402 phase 3 trial readouts approach across autoimmune indications
- Cash runway supports pipeline advancement through key catalysts
- Competition intensifies from argenxs Vyvgart in FcRn inhibitor market
| Net Income: -538.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.49 > 0.02 and ΔFCF/TA 14.54 > 1.0 |
| NWC/Revenue: 10.3k% < 20% (prev 374k%; Δ -364k% < -1%) |
| CFO/TA -0.49 > 3% & CFO -414.3m > Net Income -538.2m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.27 > 1.5 & < 3 |
| Outstanding Shares: last quarter (205.5m) vs 12m ago 20.29% < -2% |
| Gross Margin: 94.24% > 18% (prev -134.4%; Δ 228.6% > 0.5%) |
| Asset Turnover: 0.94% > 50% (prev 0.02%; Δ 0.91% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.86 (Total Current Assets 851.2m - Total Current Liabilities 117.1m) / Total Assets 852.5m |
| B: -2.23 (Retained Earnings -1.90b / Total Assets 852.5m) |
| C: -0.71 (EBIT TTM -538.9m / Avg Total Assets 757.0m) |
| D: 6.28 (Book Value of Equity 735.4m / Total Liabilities 117.1m) |
| Altman-Z'' = 0.20 = B |
| DSRI: 0.10 (Receivables 697k/1.94m, Revenue 7.09m/160k) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.08 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 44.34 (Revenue 7.09m / 160k) |
| TATA: -0.15 (NI -538.2m - CFO -414.3m) / TA 852.5m) |
| Beneish M = 26.75 (Cap -4..+1) = D |
As of August 14, 2026, the stock is trading at USD 41.82 with a total of 1,360,989 shares traded. Over the past week, the price has changed by +5.23%, over one month by +8.06%, over three months by +42.97% and over the past year by +163.18%.
Current recommended Stop Loss: 39.80 (which is 4.8% or 1.3 ATR below the current price).
Immunovant has received a consensus analysts rating of 4.64. Therefore, it is recommended to buy IMVT.
- StrongBuy: 10
- Buy: 3
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 48.3 | 15.6% |
P/B = 11.2041
Revenue TTM = 7.09m USD
EBIT TTM = -538.9m USD
EBITDA TTM = -538.5m USD
Long Term Debt = unknown (none)
Short Term Debt = 72.0k USD (from shortTermDebt, last fiscal year)
Debt = 72.0k USD (from shortLongTermDebtTotal, last fiscal year) (leases 72.0k already included)
Net Debt = -797.7m USD (calculated: Debt 72.0k - CCE 797.8m)
Enterprise Value = 8.00b USD (8.80b + Debt 72.0k - CCE 797.8m)
Interest Coverage Ratio = unknown (Ebit TTM -538.9m / Interest Expense TTM 0.0)
EV/FCF = -19.31x (Enterprise Value 8.00b / FCF TTM -414.3m)
FCF Yield = -5.18% (FCF TTM -414.3m / Enterprise Value 8.00b)
FCF Margin = -5.84k% (FCF TTM -414.3m / Revenue TTM 7.09m)
Net Margin = -7.59k% (Net Income TTM -538.2m / Revenue TTM 7.09m)
Gross Margin = 94.24% ((Revenue TTM 7.09m - Cost of Revenue TTM 409k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 9.39 (Enterprise Value 8.00b / Total Assets 852.5m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 72.0k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -425.7m (EBIT -538.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.27 (Total Current Assets 851.2m / Total Current Liabilities 117.1m)
Debt / Equity = 0.00 (Debt 72.0k / totalStockholderEquity, last quarter 735.4m)
Debt / EBITDA = 1.48 (negative EBITDA) (Net Debt -797.7m / EBITDA -538.5m)
Debt / FCF = 1.93 (negative FCF - burning cash) (Net Debt -797.7m / FCF TTM -414.3m)
Total Stockholder Equity = 773.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -71.10% (Net Income -538.2m / Total Assets 852.5m)
RoE = -69.59% (Net Income TTM -538.2m / Total Stockholder Equity 773.5m)
RoCE = -73.28% (EBIT -538.9m / Capital Employed (Total Assets 852.5m - Current Liab 117.1m))
RoIC = -57.92% (negative operating profit) (NOPAT -425.7m / Invested Capital 735.1m)
WACC = 8.92% (E(8.80b)/V(8.80b) * Re(8.92%) + D(72.0k)/V(8.80b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.92% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 94.29 | Cagr: 16.65%
[DCF] Fair Price = unknown (Cash Flow -414.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.93 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 4.0 | # QB: 1
EPS current Quarter (2026-09-30): EPS=-0.73 | Chg30d=-39.56% | Revisions=+25% | Analysts=2
EPS next Quarter (2026-12-31): EPS=-0.74 | Chg30d=-65.93% | Revisions=+25% | Analysts=2
EPS current Year (2027-03-31): EPS=-2.95 | Chg30d=-17.13% | Revisions=-17% | GrowthEPS=-19.5% | GrowthRev=+0.0%
EPS next Year (2028-03-31): EPS=-2.50 | Chg30d=-0.10% | Revisions=+25% | GrowthEPS=+15.2% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +22% (up=4, down=2)